Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.00 CHF
−18.64 M CHF
320.83 M CHF
13.02 M
About PolyPeptide Group AG
Sector
Industry
CEO
Juan-José Gonzalez
Website
Headquarters
Baar
Founded
1952
ISIN
CH1110760852
FIGI
BBG0100P02R8
PolyPeptide Group AG engages in the business of development, manufacturing, and marketing of peptide- and oligonucleotide-based compounds for use in the pharmaceutical and related research industries. It operates through the following business areas: Custom Projects, Contract Manufacturing, and Generics and Cosmetics. The Custom Projects business area includes manufacturing of custom research-grade peptides and oligonucleotides for use in pre-clinical and clinical development as well as for regulatory and scientific studies. The Contract Manufacturing business area focuses on peptides for commercial stage peptide therapeutics, at scale, in commercial batches and in accordance with current Good Manufacturing Practice (cGMP) requirements. The Generics and Cosmetics business area is involved in peptide-based generics for the human and veterinary market, produced on an industrial scale following cGMP guidelines. The company was founded in 1952 and is headquartered in Baar, Switzerland.
Related stocks
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of PPGN is 24.60 CHF — it has decreased by −1.60% in the past 24 hours. Watch PolyPeptide Group AG stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on SIX exchange PolyPeptide Group AG stocks are traded under the ticker PPGN.
PPGN stock has fallen by −6.46% compared to the previous week, the last month showed zero change in price, over the last year PolyPeptide Group AG has showed a −25.00% decrease.
We've gathered analysts' opinions on PolyPeptide Group AG future price: according to them, PPGN price has a max estimate of 44.13 CHF and a min estimate of 26.93 CHF. Watch PPGN chart and read a more detailed PolyPeptide Group AG stock forecast: see what analysts think of PolyPeptide Group AG and suggest that you do with its stocks.
PPGN reached its all-time high on Sep 6, 2021 with the price of 147.40 CHF, and its all-time low was 13.20 CHF and was reached on Apr 7, 2025. View more price dynamics on PPGN chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
PPGN stock is 5.19% volatile and has beta coefficient of 1.35. Track PolyPeptide Group AG stock price on the chart and check out the list of the most volatile stocks — is PolyPeptide Group AG there?
Today PolyPeptide Group AG has the market capitalization of 811.59 M, it has decreased by −7.19% over the last week.
Yes, you can track PolyPeptide Group AG financials in yearly and quarterly reports right on TradingView.
PolyPeptide Group AG is going to release the next earnings report on Mar 12, 2026. Keep track of upcoming events with our Earnings Calendar.
PPGN earnings for the last half-year are −0.80 CHF per share, whereas the estimation was −0.53 CHF, resulting in a −50.59% surprise. The estimated earnings for the next half-year are 0.29 CHF per share. See more details about PolyPeptide Group AG earnings.
PolyPeptide Group AG revenue for the last half-year amounts to 156.17 M CHF, despite the estimated figure of 145.11 M CHF. In the next half-year revenue is expected to reach 218.47 M CHF.
PPGN net income for the last half-year is −24.99 M CHF, while the previous report showed −7.72 M CHF of net income which accounts for −223.78% change. Track more PolyPeptide Group AG financial stats to get the full picture.
As of Sep 14, 2025, the company has 1.36 K employees. See our rating of the largest employees — is PolyPeptide Group AG on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. PolyPeptide Group AG EBITDA is 23.80 M CHF, and current EBITDA margin is 6.94%. See more stats in PolyPeptide Group AG financial statements.
Like other stocks, PPGN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade PolyPeptide Group AG stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So PolyPeptide Group AG technincal analysis shows the sell today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating PolyPeptide Group AG stock shows the sell signal. See more of PolyPeptide Group AG technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.